NEW YORK – Caris Life Sciences said Thursday that it has partnered with Meaningful Insights Biotech Analytics (MiBA) to advance precision oncology and patient care by educating providers on molecular testing.
Caris maintains a multimodal database that includes whole-genome and whole-exome sequencing data, while MiBA provides data-driven alerts to oncologists to help them decide on personalized treatments and molecular testing for their patients. Its database consists of genomic and clinical information, insurance claims, and pharmaceutical and clinical trials data.
Financial terms of the deal were not disclosed.
Under the agreement, MiBA will also implement an Oncology Insights Program in partnership with the National Community Oncology Dispensing Association to provide education and training to healthcare providers.
"By combining data insights with provider education, physicians will be guided to appropriate molecular testing for patients' specific needs across multiple cancer tumor types," Caris President David Spetzler said in a statement.
"Combining MiBA's real-world insights engine with Caris' advanced molecular capabilities will empower the oncology ecosystem with smarter, faster, and more collaborative decision-making," Mark Moch, managing partner at MiBA, said in a statement.
MiBA entered a similar partnership last year, with Guardant Health, and Caris likewise partnered with Ontada to integrate genomic and clinical cancer data.